When interfering the OX40–OX40L pathway by treatment with anti-OX40L in LDL receptor-deficient mice, an increase in IL-33 expression in the spleen of treated mice compared with control mice in parallel to the regression of atherosclerosis was observed [66]. This evidence concerns the gene TNFSF4 and atherosclerosis.